IL308095A - Dosing regimens - Google Patents

Dosing regimens

Info

Publication number
IL308095A
IL308095A IL308095A IL30809523A IL308095A IL 308095 A IL308095 A IL 308095A IL 308095 A IL308095 A IL 308095A IL 30809523 A IL30809523 A IL 30809523A IL 308095 A IL308095 A IL 308095A
Authority
IL
Israel
Prior art keywords
dosing regimens
regimens
dosing
Prior art date
Application number
IL308095A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL308095A publication Critical patent/IL308095A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL308095A 2021-05-11 2022-05-10 Dosing regimens IL308095A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (1)

Publication Number Publication Date
IL308095A true IL308095A (en) 2023-12-01

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308095A IL308095A (en) 2021-05-11 2022-05-10 Dosing regimens

Country Status (8)

Country Link
US (1) US20240245666A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337205A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518426A (cg-RX-API-DMAC7.html)
KR (1) KR20240006600A (cg-RX-API-DMAC7.html)
CN (1) CN117396202A (cg-RX-API-DMAC7.html)
CA (1) CA3218550A1 (cg-RX-API-DMAC7.html)
IL (1) IL308095A (cg-RX-API-DMAC7.html)
WO (1) WO2022238884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2670601T3 (es) * 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
CN112110880B (zh) * 2020-09-29 2022-09-09 天津红日药业股份有限公司 雄甾烷衍生物及其制备方法与应用

Also Published As

Publication number Publication date
JP2024518426A (ja) 2024-05-01
US20240245666A1 (en) 2024-07-25
KR20240006600A (ko) 2024-01-15
EP4337205A1 (en) 2024-03-20
WO2022238884A1 (en) 2022-11-17
CN117396202A (zh) 2024-01-12
CA3218550A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
IL279005A (en) Dosing regimens of anti-CD37 immunoconjugates
IL268180A (en) Dosing regimens of anti-FOLR1 immunoconjugate
IL289949A (en) Dosing regimens for oral complement factor d inhibitors
IL314891B2 (en) Dosing regimens and related compositions and methods
HUE055109T2 (hu) Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
IL244772A0 (en) Anti-folr1 immunoconjugate dosing regimens
PT4340842T (pt) Sotorasib para utilização no tratamento de cancro
IL308389A (en) Dosing regimens for acubactadine
EP4319760A4 (en) CEFTIBUTENE DOSAGE REGIMEN
CA202619S (en) Dosing device
GB2589153B (en) E-liquid
PT4127614T (pt) Dispositivo de dosagem
GB201521217D0 (en) Dosage regimens
LT4058148T (lt) Agentų prieš bcma dozavimo režimas
PL3733041T3 (pl) Urządzenie dozujące
GB2588686B (en) Chemical-agent dosing apparatus
IL280515A (en) Dosing regimens for elagolix
HK40106392A (en) Ceftibuten dosing regimens
HK40054775A (en) Dosing regimens for elagolix
HK40050925A (en) Anti-cd37 immunoconjugate dosing regimens
GB202202673D0 (en) Dosing device
GB201910963D0 (en) Dosing unit
GB202316063D0 (en) Dosing regime
GB201903654D0 (en) Dosing device
GB201902454D0 (en) Dosage regimen